CD19 antibody (AA 200-250)

Catalog No. ABIN2746372

Product Details anti-CD19 Antibody

Target: CD19 (CD19 Molecule (CD19))

Binding Specificity: AA 200-250

Reactivity: Human, Mouse, Rat

Host: Rabbit

Clonality: Polyclonal

Conjugate: This CD19 antibody is un-conjugated

Application: Western Blotting (WB), Immunohistochemistry (IHC), ELISA, Immunoprecipitation (IP)

Specificity: The antibody labels a strong band of CD19 at 67 kDa in ABIN1741617 samples and in other cancer cell lines.

Cross-Reactivity: Mouse (Murine), Rat (Rattus)

Cross-Reactivity (Details): Does not cross react to any other cellular protein.

Characteristics: CD19 selective antibodies were generated against a peptide taken from the human protein. The CD19-selective antibodies are affinity purified on an immobilized antigen based affinity matrix, the isolated antibodies were then stabilized in antibody stabilization buffer for long-term storage. The CD19-selective antibodies are fully characterized for applications in western blotting and ELISA at the recommended dilutions. The supplier provides CD19 Western blot positive control samples in ready-to-use SDS-PAGE sample buffer. Limited quantities of antigenic blocking peptide for CD19 antibody is also available, please inquire before ordering.

Purification: Affinity Purified

Immunogen: Synthetic peptide taken within amino acid region 200-250 on human CD19 protein.

Isotype: IgG

Application Details

Application Notes: Optimal working dilution should be determined by the investigator.

Comment:

Synonyms: B-lymphocyte surface antigen B4, Differentiation antigen CD19, T-cell surface antigen Leu-12, CD_antigen=CD19, B lymphocyte antigen CD19, B lymphocyte surface antigen B4 antibody, Leu12 antibody, Lymphocyte Surface Antigen antibody, MGC109570 antibody, MGC12802 antibody, T-cell surface antigen Leu-12 antibody.

Restrictions: For Research Use only

Handling

Format: Liquid

Concentration: 0.55-0.75 μg/μL

Handling Advice: Working solutions of antibodies in buffer should be filtered through 0.45 μm filter after every use for long-term storage.

Storage: -20 °C

Storage Comment: For long-term storage of keep at -20 °C. We don't recommend storage of very dilute antibody solutions unless they are prepared in specially formulated multi use antibody dilution buffer.

Target Details for CD19

Target: CD19 (CD19 Molecule (CD19))

Alternative Name: CD19 (CD19 Products)

Synonyms: B4 antibody, CVID3 antibody, AW495831 antibody, CD19 antibody, CD19 molecule antibody, CD19 antigen antibody, CD19 antibody, Cd19 antibody

Background: CD19 (Cluster of Differentiation 19) also known as B4, is a 95 kDa type-I transmembrane glycoprotein which is restricted to B cell antigen. CD19 is a cell surface molecule which assembles with the antigen receptor of B lymphocytes in order to decrease the threshold for antigen receptor-dependent stimulation. It contains two extracellular immunoglobulin-like domains and is selectively expressed on the cell surface of B-lymphocytes, where it activates intracellular signaling cascades. CD19 antigen is also found on the follicular dendritic cells and the early cells of myelomonocytic lineage but not on normal T cells, NK cells, monocytes, granulocytes, erythrocytes and platelets. In normal peripheral blood, 8-20 % of lymphocytes express CD19 antigen, but plasma cells do not express this antigen. CD19 antigen plays a role in regulating B cell proliferation.The cytoplasmic tail of CD19 has nine conserved tyrosine residues playing critical roles in CD19 mediated function by coupling signaling molecules to the receptor. After B cell receptor or CD19 ligation, Tyr531 and Tyr500 of CD19 are progressively phosphorylated. The phosphorylation at these sites mediates elevated intracellular calcium response, as well as the JNK pathway. Defects in CD19 causes common variable immunodeficiency type 3 (CVID3) also called antibody deficiency due to CD19 defect. CVID3 is characterized by hypogammaglobulinemia, recurrent bacterial infections and an inability to mount an antibody response to antigen. The defect results from a failure of B-cell differentiation and impaired secretion of immunoglobulins. Adoptive T-cell therapy with CD19-specific chimeric antigen receptors (CARs) is promising for treatment of advanced B-cell malignancies. CD19-CAR T-cells enhance the efficacy of adoptive T-cell therapy for refractory B-cell lymphoma. The human CD19 gene maps to chromosome 16p11.2 and encodes a 557 amino acid protein.

UniProt: P15391

Pathways: Fc-epsilon Receptor Signaling Pathway, EGFR Signaling Pathway, Neurotrophin Signaling Pathway